What is Mutamycin
MitomycinThe Generic name of this drug
Treatment SummaryMitomycin is an antibiotic used to treat cancer. It was first discovered in the 1950s by Japanese microbiologists and works by inhibiting the replication of DNA. It is an alkylating agent, which means it creates a cross-link between the two strands of the DNA double helix. Few other antibiotics have this same type of effect, making it a rare and unique treatment option. Mitomycin has been approved for use in a variety of cancers, as well as to reduce eye pressure during certain surgeries.
Mutamycinis the brand name
Mutamycin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mutamycin
Mitomycin
1981
46
Approved as Treatment by the FDA
Mitomycin, also called Mutamycin, is approved by the FDA for 3 uses such as Glaucoma and Pancreatic Adenocarcinoma .Glaucoma
Pancreatic Adenocarcinoma
Used to treat Adenocarcinomas of the Pancreas in combination with null
Gastric Adenocarcinoma
Used to treat Adenocarcinoma of the Stomach in combination with null
Effectiveness
How Mutamycin Affects PatientsMitomycin is an older chemotherapy drug that has been used for many years. It is an antibiotic and can help fight tumors. Mitomycin works by blocking DNA, RNA, and protein synthesis. It also can prevent cells such as B cells, T cells, and macrophages from growing, and can stop certain substances like interferon gamma, TNFa, and IL-2 from being released.
How Mutamycin works in the bodyMitomycin is activated in the body to a form that binds to DNA and prevents it from functioning properly. This binding causes areas of the DNA to link together, preventing it from replicating. Mitomycin works in all phases of the cell cycle and doesn't discriminate against any.
When to interrupt dosage
The amount of Mutamycin is contingent upon the diagnosed condition, including Gastric Adenocarcinoma, Cervical Cancer and Glaucoma. The dosage can also be found in the table below, contingent upon the method of delivery.Condition
Dosage
Administration
Gastric Adenocarcinoma
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Cervical Cancer
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Glaucoma
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Pancreatic Adenocarcinoma
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Bladder Cancer
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Head and Neck Carcinoma
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Non-Small Cell Lung Cancer
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Mesotheliomas
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Cancer, Anal
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Breast Cancer
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
low-grade Upper Tract Urothelial Cancer (LG-UTUC)
4.0 mg/mL, , 0.5 mg/mL, 40.0 mg, 2.0 mg/mL, 0.2 mg/mL, 20.0 mg, 5.0 mg
Powder, for solution - Intravenous; Intravesical, , Injection, powder, lyophilized, for solution, Kit - Ophthalmic, Injection, powder, lyophilized, for solution; Kit, Kit; Powder, for solution, Injection, powder, lyophilized, for solution; Kit - Ophthalmic, Powder, for solution, Injection, powder, for solution - Intravenous, Intravenous; Intravesical, Intravenous, Ureteral, Injection, powder, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution - Ophthalmic, Kit; Powder, for solution - Ureteral, Kit
Warnings
Mutamycin ContraindicationsCondition
Risk Level
Notes
increase in bleeding tendency
Do Not Combine
Coagulation Disorder
Do Not Combine
Low Platelet Count
Do Not Combine
Common Mutamycin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mitomycin is combined with Acteoside.
Mutamycin Toxicity & Overdose RiskThe toxic dose of the drug in mice has been found to be 23mg/kg and 30mg/kg in rats. Those who overdose on the drug may experience nausea and vomiting.
Mutamycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Mutamycin?
There are presently 1386 investigations in progress, assessing the potential of Mutamycin in managing Cervical Cancer, Bladder Cancer and Pancreatic Adenocarcinoma.Condition
Clinical Trials
Trial Phases
Bladder Cancer
106 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 1, Early Phase 1
Cervical Cancer
101 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Early Phase 1
Gastric Adenocarcinoma
41 Actively Recruiting
Phase 4, Phase 2, Phase 1, Not Applicable, Phase 3
Pancreatic Adenocarcinoma
72 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Glaucoma
0 Actively Recruiting
Head and Neck Carcinoma
21 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 1, Early Phase 1
Breast Cancer
692 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Cancer, Anal
18 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable
Mesotheliomas
0 Actively Recruiting
low-grade Upper Tract Urothelial Cancer (LG-UTUC)
0 Actively Recruiting
Non-Small Cell Lung Cancer
358 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Mutamycin Reviews: What are patients saying about Mutamycin?
3Patient Review
9/18/2014 The doctor administered this treatment via a catheter, which was uncomfortable but not painful. A few days after each treatment, I experienced a low-grade fever--this happened after every single treatment. I received six treatments in total, on a weekly basis. It's too soon to tell if the treatment was effective or not.
3Patient Review
2/28/2020 The surgery to remove the tumor was successful, and now I've started chemo. So far it's been tough because of fatigue, but it's only my third treatment.
3Patient Review
9/18/2014 The doctor administering this treatment was via a catheter, which was uncomfortable but not painful. A few days after each treatment, I experienced a low-grade fever similar to the flu. This happened after every weekly treatment. It's too soon to tell if the treatments were effective.
3Patient Review
2/28/2020 The surgery to remove the tumor went well, and chemo has been manageable so far. The fatigue has been the worst part, but I'm almost done with treatment.
1.3Patient Review
3/11/2010 Unfortunately, this medication caused a number of issues for me, including a skin rash, fatigue, and irritation/itching around my bladder and urethra.
1.3Patient Review
3/11/2010 I unfortunately had a lot of negative side effects from this treatment, including a skin rash, fatigue, and irritation/itching around my bladder and urethra.
Patient Q&A Section about mutamycin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How do you give a Mitomycin injection?
"In cytostatic monochemotherapy mitomycin is usually given as an intravenous injection all at once. The recommended dosage is 10 - 20 mg/m2 of body surface every 6 - 8 weeks, 8 - 12 mg/m2 of body surface every 3 - 4 weeks, or 5-10 mg/m2 of body surface every 1-6 weeks depending on which therapeutic scheme is used."
Answered by AI
When is Mitomycin used for bladder cancer?
"The chemotherapy drug Mitomycin is used to kill any cancer cells that may have remained in your bladder after surgery. The drug remains in your bladder for one to two hours and is then drained out through the urinary catheter, or leaves your bladder when you pass urine."
Answered by AI
What is Mitomycin used for?
"Mitomycin is an antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells."
Answered by AI
Is Mitomycin a chemotherapy?
"Mitomycin C is a chemotherapy drug that treats various types of cancer."
Answered by AI